In vitro identification of the cytochrome P450 isoform responsible for the metabolism of a-dihydroergocryptine

References

• BALL, S. E., MAURER, G., ZOLLINGER, M., LADONA, M. and VICKERS, A. E. M., 1992, Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metabolism and Disposition, 20,56–63.
   PubMed Web of Science ®Google Scholar
• BARRY, M., MULCAHY, F., MERR, C., GIBBONS, S. and BACK, D., 1999, Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clinical Pharmacokinetics, 36, 289–304.
   PubMed Web of Science ®Google Scholar
• BATTISTIN, L., BARDIN, P., G., FERRO-MILONE, F., RAVENNA, C., Toso, V. and REBOLDI, G., 1999, Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurologica Scandinavica, 99, 36–42.
   Google Scholar
• BEIERLE, I., MEIBOHM, B. and DERENDORF, H., 1999, Gender differences in pharmacokinetics and pharmacodynamics. International journal of Clinical Pharmacology and Therapeutics, 37,529–547.
   PubMed Web of Science ®Google Scholar
• BERGAMASCO, B., FRATTOLA, L., MURATORI°, A., PICCOLI, F. and PARNETTI, L., 2000, Alpha-dihydroergocryptine in the treatment of de now Parkinsonian patients: results of a multicentre, randomized, double blind, placebo-controlled study. Acta Neurologka Scandinavica, 101, 372–380.
   Google Scholar
• BORT, R., MACE., K., BOOBIS, A., GOmEz-LEcHON, M.-J., PFEIFER, A. and CASTELL, J., 1999, Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochemical Pharmacology, 58, 787–796.
   Google Scholar
• CORREIA, A. M., 1998, Drug biotransformation. In B. G. Katzung (ed.), Basic & Clinical Pharmacology, 7th edn (Stamford: Appleton & Lange), pp. 50–61.
   Google Scholar
• DELAFORGE, M., RIVI'ÈRE, R., SARTORI, E., DOIGNON, J. L. and GROGNET, J. M., 1989, Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica, 19, 1285–1295.
   Google Scholar
• DOEHMER, J., 1993, V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies. Toxicology, 82, 105–118.
   PubMed Web of Science ®Google Scholar
• DRESSER, G. K., SPENCE, J. D. and BAILEY, D. G., 2000, Pharmacokinetic-pharmacodynamic con-sequences and clinical relevance of cytochrome P450 3A4 inhibition. Drug Interactions, 38,41–57.
   Google Scholar
• EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• FLOCKHART, D. A., 2000, Cytochrome P450 drug interaction table, Georgetown University Medical Center, Division of Clinical Pharmacology [http ://www.dml.georgetown.edu /depts/ pharmacology /davetab.html].
   Google Scholar
• GOmEz-LEcHON, M.-J., LOPEZ, P., DONATO, T., MONTOYA, A., LARRAURI, A., GIMEN TRULLENQUE, R., FABRA, R. and CASTELL, J. V., 1990, Culture of human hepatocytes from small surgical biopsies. Biochemical characterization and comparison with in vivo. In Vitro Cellular and Developmental Biology, 26, 67–74.
   Google Scholar
• KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S., MERION, R. M. and WATKINS, P. B., 1994, CYP3A gene expression in human gut epithelium. Pharmaco-genetics, 4, 247–259.
   Google Scholar
• LEWIS, D. F., DICKINS, M., EDDERSHAW,P. J., TARBIT, M. H. and GOLDFARB, P. S., 1999, Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries. Drug Metabolism and Drug Interacticn, 15, 1–49.
   Google Scholar
• MACE, K., AGUILAR F., WANG, J. S., VAUTRAVERS, P., GOmEz-LEcHON, M., GONZALEZ, F. J., GROOPMAN, J., HARRIS, C. C. and PFEIFER, A. M., 1997, Afiatoxin B1 -induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis, 18, 1291–1297.
   Google Scholar
• MARKSTEIN, R., 1983, Dopamine receptor profile of co-dergocrine (Hydergine-) and its components. European journal of Pharmacology, 86, 145–155.
   Web of Science ®Google Scholar
• MAS-CHAMBERLIN, C., BROMET, N., OLGIATI, V., GIRADELLO, R, and LOWENTHAL, D. T., 1997, Metabolism study of dihydro-a-ergocryptine,9,10-[9,10-3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes. American journal of Therapeutics, 4, 291–299.
   PubMedGoogle Scholar
• MAURER, G., 1977, Isolement et Structure de Metabolites Biliaires de la Dihydro-fl-ergokryptine chez le Rat. Doctoral thesis, University Claude Bernard, Lyon I, pp. 1–184.
   Google Scholar
• MAURER, G. and FRICK, W., 1984, Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man. European journal of Clinical Pharmacology, 26, 463–470.
   PubMed Web of Science ®Google Scholar
• MAURER, G., SCHREIER, E., DELABORDE, S., LOOSLI, H. R., NUFER, R. and SHUKLA, A. P., 1982, Fate and disposition of bromocriptine in animals and man. I: Structure and elucidation of the metabolites. European journal of Drug Metabolism and Pharmacokinetics, 7, 281–292.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., 1999, Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes [Review]. International Journal of Molecular Medicine, 3, 227–238.
   PubMed Web of Science ®Google Scholar
• NELSON, M. V., BERCHOU, R. C., KARETTI, D. and LEWITT, P. A., 1990, Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clinical Pharmacology and Thera-peutics, 47, 694–697.
   PubMed Web of Science ®Google Scholar
• PEYRONNEAU, M.-A., DELAFORGE, M., RIVIERE, R., RENAUD, J.-P. and MANSUY, D., 1994, High affinity of ergopeptides for cytochrome P450 3A. European Journal of Biochemistry, 223, 947–956.
   PubMedGoogle Scholar
• PFEIFER, A. M., COLE, K. E., SMOOT, D. T., WESTON, A., GROOPMAN, J. D., SHIELDS, P. G., VIGNAUD, J. M., JUILLERAT, M., LIPSKY, M. M., TRUMP, B. F., LECHNER, J. F. and HARRIS, C. C., 1993, Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proceedings of the National Academy of Sciences, USA, 90, 5123–5127.
   PubMed Web of Science ®Google Scholar
• PFEIFER, A. M., MACK, K., TROMVOUKIS, Y. and LIPSKY, M. M., 1995, Highly efficient establishment of immortalized cells from adult human liver. Methods of Cellular Science, 17, 83–89.
   Google Scholar
• PLATT, K. L., MOLITOR, E., D6HMER. J., DOGRA, S. and OESCH, F., 1989, Genetically engineered V79 Chinese hamster cell expression of purified cytochrome P-45011BI monooxygenase activity. Journal of Biochemical Toxicology, 4, 1–6.
   Google Scholar
• RAUSCHENBACH, R., GIESCHEN, H., HUSEMANN, M., SALOMON, B. and HILDEBRAND, M., 1995, Stable expression of human P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. European Journal of Pharmacology Environmental Toxicology and Pharmacology Section, 293, 183–190.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-ANTONA, C., GOMEZ-LECHON, M. J. and CASTELL, J. V., 2000, Quantitative RT-PCR measurement of human cytochrome P-450 application to drug induction studies. Archives of Biochemistry and Biophysics, 376, 109–116.
   Google Scholar
• RONCA, F., GUAZZELLI, M., SALVADORI, O., PALUMBO, R., NEUTEBOOM, B., AMBROSOLI, L., POLI, A., GIRADELLO, R. and LoWENTHAL, D. T., 1996, Pharmacokinetic and metabolism study in healthy volunteers after administration of single oral dose of 3H-a-dihydroergocryptine mesylate. American Journal of Therapeutics, 3, 553–562.
   PubMedGoogle Scholar
• TANAKA, E., 1999, Gender-related differences in pharmacokinetics and their clinical significance. Journal of Clinical Pharmacy and Therapeutics, 24, 339–346.
   PubMed Web of Science ®Google Scholar
• WYNALDA, M. A. and WIENKERS, L. C., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metabolism and Disposition, 25, 1211–1214.
   PubMed Web of Science ®Google Scholar